Intradermal Acupuncture Based on Changes in Biological Specificity of Acupoints for Major Depressive Disorder

• Status: Recruiting
• Trial end date: 2025-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Acupoints are the stimulus points and reactive points for acupuncture to treat diseases. Therefore, this study is designed to detect the pain threshold and temperature of biological specificities of acupoints in healthy control (HC) participants and major depressive disorder (MDD) participants by using pressure pain threshold gauge (PTG) and infrared thermography (IRT). Based on the results of the PTG and IRT tests, the potentially superior acupoints for the treatment of MDD will be selected separately. Then, different acupoint groups selected based on different biological specificities tests will be used for clinical treatment to evaluate the clinical efficacy of intradermal acupuncture (IA) for MDD based on changes in the biological specificities of acupoints.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The Third Affiliated hospital of Zhejiang Chinese Medical University
• Collaborators: First People's Hospital of Hangzhou; Zhejiang Provincial Tongde Hospital
• Treatments: Antidepressive Agents

Criteria

Inclusion Criteria:

Inclusion criteria for HC:

• HC who could provide a recent depression screening report, and confirm they have not any cardiovascular, respiratory, digestive, urinary, hematological, endocrine, or neurological disease;

• 18 ≤ age ≤60 years, male or female;

• Participants have clear consciousness and could communicate with others normally;

• Participants could understand the full study protocol and have high adherence. Written informed consent is signed by themselves.

Inclusion criteria for MDD:

• Patients should meet the diagnostic criteria of the International Classification of Diseases 10th Edition (ICD-10) diagnostic criteria for MDD;

• 18 ≤ age ≤60, male or female;

• Participants have clear consciousness and could communicate with others normally;

• Participants could understand the full study protocol and have high adherence. Written informed consent is signed by themselves.

Exclusion Criteria:

Exclusion criteria of HC:

• Participants with serious primary diseases of cardiovascular diseases, liver diseases, kidney diseases, urinary diseases, and hematological diseases;

• Participants have a mental illness, alcohol dependence, or a history of drug abuse;

• Pregnant or lactating participants;

• Participants with intellectual disabilities who cannot cooperate with the questionnaire survey;

• Participants with bleeding tendency, skin disease, allergic constitution, and allergic to adhesive tape;

• The skin at the test site of participants has scars, hyperpigmentation, red and swollen;

• Participants are participating in other trials.

Exclusion criteria for MDD:

• Participants with serious primary diseases of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, neurological disease, and other serious primary diseases, and the disease cannot be effectively controlled clinically;

• MDD caused by organic mental disorders, schizophrenia, bipolar disorder, psychoactive substances, and non-addictive substances;

• Participants with suicidal tendencies;

• Pregnant or lactating participants;

• Participants with intellectual disabilities who cannot cooperate with the questionnaire survey;

• Participants with bleeding tendency, skin disease, allergic constitution, and allergic to adhesive tape;

• The skin at the test site of participants has scars, hyperpigmentation, red and swollen. IRT is not be performed on female subjects during their menstrual and ovulatory periods;

• Participants are participating in other trials.